Viral proteinases: Targets of opportunity

Drug Development Research

Volumn 67, Issue 6, 2006, Pages 501-510

  Byrd, Chelsea M ^a   Hruby, Dennis E ^a,b  

^a SIGA Technologies Incorporated   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Antiviral drugs; I7L; Proteinase inhibitors; Vaccinia virus

Indexed keywords

ABACAVIR; ACICLOVIR; ADEFOVIR DIPIVOXIL; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSCARNET; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PENTAERYTHRITYL TETRANITRATE; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A; LIFE CYCLE; NONHUMAN; REVIEW; VACCINIA VIRUS; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

EID: 33750358280     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20114     Document Type: Review

References (68)

1. Ansarah-Sobrinho C, Moss B. 2004a. Role of the 17 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol 78:6335-6343.
2. Ansarah-Sobrinho C, Moss B. 2004b. Vaccinia virus G1 protein, a predicted metalloprotease, is essential for morphogenesis of infectious virions but not for cleavage of major core proteins. J Virol 78:6855-6863.
3. Barista I. 2000. Intrathecal cytarabine and bone marrow suppression. J Clin Oncol 18:2003-2004.
4. Barrett AJ, Rawlings ND, Woessner JF, editors. 2004. Handbook of proteolytic enzymes, 2nd ed. San Diego: Elsevier Academic Press.
5. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633-642.
6. Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patiek AK. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619-626.
7. Burton A. 2003. Enfuvirtide approved for defusing HIV Lancet Infect Dis 3:260.
8. Byrd CM, Hruby DE. 2005a. A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis. Virol J 2:4.
9. Byrd CM, Hruby DE. 2005b. Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity. Virol J 2:63.
10. Byrd CM, Bolken TC, Hruby DE. 2002. The vaccinia virus I7L gene product is the core protein proteinase. J Virol 76:8973-8976.
11. Byrd CM, Bolken TC, Hruby DE. 2003. Molecular dissection of the vaccinia virus I7L core protein proteinase. J Virol 77: 11279-11283.
12. Byrd CM, Bolken TC, Mjalli AM, Arimilli MN, Andrews RC, Rothlein R, Andrea T, Rao M, Owens KL, Hruby DE. 2004a. New class of orthopoxvirus antiviral drugs that block viral maturation. J Virol 78:12147-12156.
13. Byrd CM, Bolken TC, Hruby DE. 2004b. Vaccinia virus metalloproteinase. In: Barrett A, Rawlings N, Woessner J, editors. Handbook of proteolytic enzymes, 2nd ed. Amsterdam: Elsevier.
14. Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G. 2005. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 79:13963-13973.
15. Cantell K. 1995. Development of antiviral therapy with alpha interferons: promises, false hopes and accomplishments. Ann Med 27:23-28.
16. Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Torok TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L, Vellozzi C, McCauley M, Strikas RA, Mootrey G. 2005. Adverse events associated with smallpox vaccination in the United States, January-October 2003. Jama 294:2734-2743.
17. Chen RY, Kilby JM, Saag MS. 2002. Enfuvirtide. Expert Opin Invest Drug 11:1837-1843.
18. Cohen HW, Gould RM, Sidel VW. 2006. Smallpox vaccinations and adverse events. JAMA 295:1897-1898.
19. De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Favia G, Serpico R. 2004. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 29:605-607.
20. Dougherty WG, Semler BL. 1993. Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol Rev 57:781-822.
21. Fleischer R, Laessig K. 2003. Safety and efficacy evaluation of pleconaril for treatment of the common cold. Clin Infect Dis 37:1722.
22. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37:251-271.
23. Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, Katlama C, Viard JP, Treluyer JM, Rouzioux C. 2004. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Aids 18:1958-1961.
24. Hanna L. 1999. T-20: first of a new class of anti-HIV drugs. Beta 12:7-8.
25. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ 3rd, Zalman LS. 2003. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47:3907-3916.
26. Hedengren-Olcott M, Byrd CM, Watson J, Hruby DE. 2004. The vaccinia virus G1L putative metalloproteinase is essential for viral replication in vivo. J Virol 78:9947-9953.
27. Hellen CU, Wimmer E. 1992. The role of proteolytic processing in the morphogenesis of virus particles. Experientia 48:201-215.
28. Herrmann EC Jr. 1968. Sensitivity of herpes simplex virus, vaccinia virus, and adenoviruses to deoxyribonucleic acid inhibitors and thiosemicarbazones in a plaque suppression test. Appl Microbiol 16:1151-1155.
29. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Cronlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
30. Hostetler KY, Richman DD, Forssen EA, Selk L, Basava R, Gardner MF, Parker S, Basava C. 1994. Phospholipid prodrug inhibitors of the HIV protease. Antiviral activity and pharmacokinetics in rats. Biochem Pharmacol 48:1399-1404.
31. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100:7271-7276.
32. Ingallinella P, Bianchi E, Ingenito R, Koch U, Steinkuhler C, Altamura S, Pessi A. 2000. Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease. Biochemistry 39:12898-12906.
33. Johnson CA, Forster TH, Winterford CM, Allan DJ. 1992. Hydroxyurea induces apoptosis and regular DNA fragmentation in a Burkitt's lymphoma cell line. Biochim Biophys Acta 1136:1-4.
34. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. 2005. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 13:125-131.
35. Jordan R, Hruby D. 2006. Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev Anti Infect Ther 4:277-289.
36. Kanda T, Basu A, Steele R, Wakita T, Ryerse JS, Ray R, Ray RB. 2006. Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol 80:4633-4639.
37. Kay J, Dunn BM. 1990. Viral proteinases: weakness in strength. Biochim Biophys Acta 1048:1-18.
38. Kempf DJ, Marsh KC, Paul DA, Knigge MF, Norbeck DW, Kohlbrenner WE, Codacovi L, Vasavanonda S, Bryant P, Wang XC, Wideburg NE, Clement JJ, Plattner JJ, Erickson J. 1991. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 35:2209-2214.
39. Krausslich HG, Wimmer E. 1988. Viral proteinases. Annu Rev Biochem 57:701-754.
40. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
41. Lagging LM, Meyer K, Owens RJ, Ray R. 1998. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol 72:3539-3546.
42. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. 2003. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. Aids 17:691-698.
43. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
44. Leung D, Abbenante G, Fairlie DP. 2000. Protease inhibitors: current status and future prospects. J Med Chem 43:305-341.
45. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
46. Long AC, Orr DC, Cameron JM, Dunn BM, Kay J. 1989. A consensus sequence for substrate hydrolysis by rhinovirus 3C proteinase. FEBS Lett 258:75-78.
47. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342.
48. Magden T, Kaariainen L, Ahola T. 2005. Inhibitors of virus replication: recent developments and prospects. Appl Microbiol Biotechnol 66:612-621.
49. Matsumoto H, Matsuda T, Nakata S, Mitoguchi T, Kimura T, Hayashi Y, Kiso Y. 2001. Synthesis and biological evaluation of prodrug-type anti-HIV agents: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse trauscriptase inhibitor. Bioorg Med Chem 9:417-430.
50. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, Villafranca JE, Janson CA, McElroy HE, Gribskov CL, Worland S. 1994. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77:761-771.
51. Nahata MC. 1987. Clinical use of antiviral drugs. Drug Intell Clin Pharm 21:399-405.
52. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ. 2005. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 49:2267-2275.
53. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. 2005. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 49:4492-4499.
54. Polgar L. 1989. Mechanisms of protease action. Boca Raton, FL: CRC Press.
55. Reeves JD, Piefer AJ. 2005. Emerging drug targets for antiretroviral therapy. Drugs 65:1747-1766.
56. Robertson D. 2003. US FDA approves new class of HIV therapeutics. Nat Biotechnol 21:470-471.
57. Rosenkranz HS, Rose HM, Morgan C, Hsu KC. 1966. The effect of hydroxyurea on virus development. II. Vaccinia virus. Virology 28:510-519.
58. Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. 2005. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. Jama 294: 2744-2750.
59. Steinbrook R. 2003. HIV infection: a new drug and new costs. N Engl J Med 348:2171-2172.
60. Steinkuhler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, De Francesco R. 1998. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37:8899-8905.
61. Valli MB, Serafino A, Crema A, Bertolini L, Manzin A, Lanzilli G, Bosman C, Iacovacci S, Giunta S, Ponzetto A, Clementi M, Carloni G. 2006. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J Med Virol 78:192-201.
62. Vella S. 1995. Update on HIV protease inhibitors. AIDS Clin Care 7:79-82, 88.
63. Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-1458.
64. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW. 1986. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324:572-575.
65. Whitehead SS, Hruby DE. 1994. A transcriptionally controlled trans-processing assay: putative identification of a vaccinia virus-encoded proteinase which cleaves precursor protein P25 K. J Virol 68:7603-7608.
66. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RLM, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79:13139-13149.
67. Yasunaga T, Sagata N, Ikawa Y. 1986. Protease gene structure and env gene variability of the AIDS virus. FEBS Lett 199: 145-150.
68. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103:2310-2315.